Physician profile
Ranjit Suri
NPI 1992704571
$41,650.96
in general payments reported to CMS, 2019-2025
33 companies · $8,636 in 2025
The $8,636 reported for 2025 was more than what 77% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $6,628 · 2021: $4,399 · 2022: $2,621 · 2023: $1,174 · 2024: $5,014 · 2025: $8,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,878 · Travel and Lodging: $6,704 · Entertainment: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,878.30 |
| Travel and Lodging | $6,703.90 |
| Entertainment | $242.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $11,244.75 | 2019-2025 | Biomonitor, Solia, Selectra |
| Sanofi-Aventis U.S. LLC | $8,206.81 | 2019-2023 | |
| Boston Scientific Corporation | $5,889.96 | 2020-2025 | Farapulse, Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Abbott Laboratories | $4,797.99 | 2019-2025 | Ensite, Navitor, Amplatzer Amulet |
| Medtronic, INC. | $2,223.64 | 2021-2025 | Linq II, Micra, Selectsecure |
| Bardy Diagnostics, INC. | $1,994.06 | 2020-2022 | |
| Medtronic Vascular, INC. | $1,496.08 | 2019-2020 | |
| Stereotaxis INC | $945.25 | 2019-2024 | Genesis, Niobe |
| Cvrx, INC. | $893.10 | 2021-2022 | |
| Elutia, INC. | $649.80 | 2019 | |
| Biosense Webster, INC. | $624.60 | 2019-2025 | Carto 3 |
| Janssen Pharmaceuticals, INC | $530.26 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $404.35 | 2019-2021 | |
| Impulse Dynamics (USA) INC. | $152.45 | 2021-2022 | |
| Pfizer INC. | $151.44 | 2019-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $150.05 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.97 | 2019-2023 | Eliquis |
| Abiomed | $124.66 | 2025 | |
| Altathera Pharmaceuticals LLC | $123.32 | 2023 | Sotalol Hydrochloride |
| Novartis Pharmaceuticals Corporation | $112.96 | 2021-2022 | |
| Teleflex LLC | $109.23 | 2025 | Orsiro Mission |
| Kestra Medical Technology Services, INC. | $107.98 | 2023-2024 | Assure Wcd |
| Philips North America LLC | $99.44 | 2022-2023 | |
| Atricure, INC. | $83.93 | 2021-2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Lundbeck LLC | $76.03 | 2019-2020 | |
| Vital Connect, INC | $67.16 | 2023-2025 | Vitalpatch Rtm |
| Cardiva Medical, INC. | $50.01 | 2019-2020 | |
| Baylis Medical Company INC | $47.45 | 2021 | |
| Alnylam Pharmaceuticals INC. | $38.33 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.64 | 2022 | |
| Amarin Pharma, INC. | $36.28 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $29.66 | 2021 | |
| Akcea Therapeutics, INC. | $28.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranjit Suri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.